Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Pilla

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Vascular and Interventional Radiology : JVIR|June 23, 2012
Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patientsMassimo Venturini, Lorenzo Pilla, Giulia Agostini, et al.
Blood|January 17, 2004
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cellsCristina Tecchio, Veronica Huber, Patrizia Scapini, et al.
Cancer Research|May 4, 2005
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96Lorenzo Pilla, Paola Squarcina, Jorgelina Coppa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2003
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cellsLicia Rivoltini, Chiara Castelli, Matteo Carrabba, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European CohortJulien Taïeb, Lina Sayah, Kathrin Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Vascular and Interventional Radiology : JVIR|June 23, 2012
Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patientsMassimo Venturini, Lorenzo Pilla, Giulia Agostini, et al.
Blood|January 17, 2004
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cellsCristina Tecchio, Veronica Huber, Patrizia Scapini, et al.
Cancer Research|May 4, 2005
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96Lorenzo Pilla, Paola Squarcina, Jorgelina Coppa, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 23, 2003
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cellsLicia Rivoltini, Chiara Castelli, Matteo Carrabba, et al.
The Lancet. Oncology|August 17, 2012
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trialAnna Maria Di Giacomo, Paolo A Ascierto, Lorenzo Pilla, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2023
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European CohortJulien Taïeb, Lina Sayah, Kathrin Heinrich, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Cancer Research|May 3, 2006
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursorsTiziana Di Pucchio, Lorenzo Pilla, Imerio Capone, et al.
Cancer Immunology, Immunotherapy : CII|April 17, 2013
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell responseChiara Camisaschi, Paola Filipazzi, Marcella Tazzari, et al.
Journal for Immunotherapy of Cancer|February 16, 2021
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patientsVeronica Huber, Lorenza Di Guardo, Luca Lalli, et al.
Pageof 4